Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Next Previous
Search
Trial Profile

An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 29 Nov 2023 Status changed from recruiting to completed.
  • 01 Apr 2022 New trial record
  • 19 Feb 2022 According to results presented at the 2022 Genitourinary Cancers Symposium, recruitment of this is ongoing until Jan 2022 and follow-up until July 2023.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top